Acumen Pharmaceuticals Inc Stock Ownership - Who owns Acumen Pharmaceuticals?

Insider buying vs selling

Have Acumen Pharmaceuticals Inc insiders been buying or selling?
Matt ZugaCFO and Chief Business Officer2022-12-2950,000$1.19

1 of 1

ABOS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ABOS insiders and whales buy or sell their stock.

ABOS Shareholders

What type of owners hold Acumen Pharmaceuticals Inc stock?
Ra Capital Management LP23.82%9,770,773$50.51MInstitution
Deep Track Capital LP9.63%3,952,000$20.43MInstitution
Robert D. Hardie9.41%3,859,141$19.95MInsider
Sands Capital Ventures Discovery Fund Iii LP8.33%3,417,075$17.67MInsider
Sands Capital Ventures LLC8.33%3,417,075$17.67MInstitution
Laurion Capital Management LP2.94%1,206,548$6.24MInstitution
Great Point Partners LLC2.56%1,051,267$5.44MInstitution
Paul B. Manning1.82%747,694$3.87MInsider
Vanguard Group Inc1.79%734,737$3.80MInstitution
Blackrock Inc1.64%671,631$3.47MInstitution

1 of 3

ABOS vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ABOS63.62%22.50%Net Buying
BIVI3.25%96.75%Net BuyingNet Selling
VSTM65.71%34.29%Net SellingNet Selling
PDSB24.90%38.04%Net Buying

Acumen Pharmaceuticals Stock Ownership FAQ

Who owns Acumen Pharmaceuticals?

Acumen Pharmaceuticals (NASDAQ: ABOS) is owned by 63.62% institutional shareholders, 22.50% Acumen Pharmaceuticals insiders, and 13.88% retail investors. Robert D. Hardie is the largest individual Acumen Pharmaceuticals shareholder, owning 3.86M shares representing 9.41% of the company. Robert D. Hardie's Acumen Pharmaceuticals shares are currently valued at $19.10M.

If you're new to stock investing, here's how to buy Acumen Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.